Leuko has raised Series A funding worth $5m for the validation of its non-invasive white blood cell (WBC) monitoring solution, PointCheck, for people with cancer.

HTH VC, Nina Capital, IAG Capital Partners, Good Growth Capital and angel investors all contributed to the funding. 

PointCheck is a technology that aids in the monitoring of WBCs in an at-home setting.

To monitor WBC levels without taking a blood sample collection, patients simply place a finger on the PointCheck device for a minute each day. 

The device is connected to the internet and sends the collected data to the patient’s care team.

The care team can then triage the findings to provide suitable, preventive therapies for patients according to a clinician’s guidance. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Leuko noted that the solution showed diagnostic precision and usability in the at-home setting in recently published studies.

The latest funding will expedite the clinical trials necessary for the solution to obtain regulatory clearance.

The company plans to carry out the trials in partnership with various cancer centres, including Dexeus and Hospital 12 de Octubre in Europe, and Boston Medical Center and MD Anderson in the US. 

Leuko co-founder and CEO Dr Carlos Castro-Gonzalez said: “Low WBC levels is one of the most common as well as most devastating and costliest side effects of cancer chemotherapy. 

“Clinical data indicates that as many as one out of every six chemotherapy patients suffer life-threatening infections and hospital readmissions directly linked to low WBCs. 

“At Leuko, we are working on a solution to help patients and providers prevent these hospital readmissions and improve clinical outcomes, by remotely monitoring WBC levels before infections ensue.”